Trajectories of metabolic and inflammatory biomarkers ten years before cancer diagnosis and the risk of subsequent severe infections: a Swedish population-based cohort study

Dang Wei,[1,2,#] Donghang Zhang,[3,4,#] Qiaoxue Liu,[5,6,#] Niklas Hammar,[1] Kejia Hu,[1] Maria Feychting,[1] Qianwei Liu,[5,6,*] Fang Fang[1]

1. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
2. Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, USA
3. Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China
4. Laboratory of Anesthesia and Critical Care Medicine, National-Local Joint Engineering Research Centre of Translational Medicine of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China
5. Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
6. Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China

# DW, DHZ, and QXL contributed equally to the work.

*Corresponding to: Qianwei Liu, Department of Hematology, Nanfang Hospital, Southern Medical University, No.1838, North Guangzhou Avenue, Guangzhou, 510515, China. Phone: +86 156 2059 7030, Email: qianweiliu@smu.edu.cn

Word count: 3127

Abstract

Background

Blood-based metabolic and inflammatory biomarker levels prior to diagnosis might be associated with the risk of severe infections among cancer patients.

Objectives

To investigate the longitudinal trajectories of circulating metabolic and inflammatory biomarkers before cancer diagnosis and assess their associations with the risk of severe infections after cancer diagnosis.

Methods

We conducted a cohort study including 10,837 patients with a first diagnosis of cancer during 1985-2005 within the Swedish AMORIS (Apolipoprotein-related MOrtality RISk) cohort. Severe infections were identified as a hospitalization for infectious diseases or a diagnosis of sepsis after cancer diagnosis throughout December 31, 2020. We focused on 18 biomarkers to identify biomarker trajectories during the 10 years before cancer diagnosis using latent class growth modeling. Through flexible parametric models, we then visualized and calculated hazards and hazard ratios (HRs) with 95% confidence intervals (CIs) of severe infections after cancer diagnosis in relation to different biomarker trajectories.

Results

The included patients had a mean (SD) age at diagnosis of 65.9 (11.7), including 5476 men (50.5%) and 9385 who were born in Sweden (86.6%). A total of 3752 (34.6%) patients were hospitalized for infectious diseases whereas 1709 (15.8%) had a diagnosis of sepsis after cancer diagnosis. We identified several distinct trajectories for the selected biomarkers during the 10 years before cancer diagnosis. A 25% to 65% higher hazard of hospitalization for infectious diseases was observed in patients with persistently high levels of glucose [HR (95%CI): 1.54 (1.34–1.78)], fructosamine [1.65 (1.38–1.97)], or triglycerides [1.25 (1.13-1.37)], compared to patients with persistently low levels. An opposite trend was however noted for total cholesterol and high-density lipoprotein. Further, compared to patients with persistently low levels, patients with increasing levels of C-reactive protein [1.25 (1.10-1.43)] and immunoglobulin G [1.85 (1.24-2.76)] had an increased risk of hospitalization for infectious diseases after cancer diagnosis. Similar results were observed for sepsis.

Conclusion

Temporal trajectories in metabolic and inflammatory biomarkers during the 10 years before cancer diagnosis were linked to an altered risk of severe infections after cancer diagnosis. Longitudinal measurement of these biomarkers before cancer diagnosis, may therefore help provide a more comprehensive assessment of the risk for severe infections among cancer patients.

Introduction

Cancer represents a major public health challenge, with 20 million new cases reported in 2022, accounting for approximately one in six deaths worldwide.(1) Severe infections, including sepsis, are common and serious complications in cancer patients, potentially disrupting treatment, deteriorating health, and leading to fatal outcomes.(2-4) Autopsy studies have for instance revealed that approximately 60% of death in patients with hematological malignancies are likely caused by infection.(2, 5) Identifying cancer patients at increased risk of severe infections is therefore essential for improving cancer survivorship. Further, as the risk of sepsis — one of the most severe and life-threatening infections — is highest in the period immediately following a cancer diagnosis,(6) the assessment of the risk for severe infections already at the time of cancer diagnosis may be particularly important. Different pre-diagnostic factors have indeed been associated with the risk of infection after cancer diagnosis, including immune deficiencies, pre-existing comorbidities (e.g., diabetes and psychiatric disorders), poor nutritional status, and prior antimicrobial use,(2, 3, 6) highlighting the important roles of immune responses and metabolic pathways.

Nevertheless, knowledge about temporal trends in metabolic and inflammatory biomarkers before cancer diagnosis and their relationship to post-cancer infection risk remains limited. A few prior studies focusing on pancreatic cancer reported that cancer patients exhibited decreasing levels of total cholesterol (TC) and low-density lipoprotein (LDL), as well as increasing levels of glucose prior to the diagnosis, compared to cancer-free individuals.(7, 8) However, whether this holds true for other cancer types remains unknown. Further, whether the temporal trends of these biomarkers before diagnosis could be indicative of the risk of severe infections among cancer patients has rarely been examined, to our best knowledge. To address these knowledge gaps, we used the Swedish AMORIS (Apolipoprotein-related MOrtality RISk) cohort to investigate the longitudinal trajectories of 18 metabolic and inflammatory biomarkers in blood during the 10 years before a cancer diagnosis, as well as the associations of such trajectories with the risk of severe infections following the cancer diagnosis.

Methods

Study design and population

The Swedish AMORIS cohort includes 812,073 individuals who underwent blood or urine laboratory tests for outpatient visits or regular health check-ups in the occupational setting during 1985-1996 in Stockholm.(9) A total of 634,981 individuals had data on blood tests during the inclusion period. Through the unique personal identification number assigned to each Swedish resident, the AMORIS cohort has been linked to several national population and health registers, including the Swedish Cancer Register, the Swedish Patient Register, the Causes of Death Register, and the Total Population Register. Cancer diagnoses were identified in the Cancer Register through the end of 2020, using the Swedish adaptation of the seventh revision of the International Classification of Diseases (ICD), which has been in use

since the register was established (Table S1). As we focused on biomarker trajectories within 10 years before a cancer diagnosis, we conducted a cohort study including patients who were diagnosed with their first cancer during 1985-2005 in the AMORIS cohort. To evaluate quadratic changes in temporal patterns of biomarker trajectories, we restricted the analysis to cancer patients who had undergone at least three health examinations with blood biomarker measurements prior to diagnosis, yielding 10,837 eligible patients (Figure 1). No substantial differences were found between patients included in this analysis and cancer patients diagnosed during 1985-2005 with fewer than three blood tests prior to cancer diagnosis (Table S2). We then followed all eligible patients from the date of cancer diagnosis to a first event of severe infection (identified through the Patient Register), emigration (identified through the Total Population Register), death (identified through the Causes of Death Register), or December 31, 2020, whichever came first.

Metabolic and inflammatory biomarkers

We focused on 18 metabolic and inflammatory blood biomarkers which were commonly measured in the AMORIS cohort (i.e., available among at least 20% of the cohort population), including glucose, fructosamine, TC, high-density lipoprotein (HDL), LDL, LDL/HDL ratio, triglycerides, apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), ApoB/ApoA1 ratio, albumin, uric acid, haptoglobin, leukocyte, immunoglobulin G (IgG), C-reactive protein (CRP), hemoglobin, and globulin. LDL concentrations were mainly calculated using the Jungner formula, while HDL concentrations were derived from TC, triglycerides, and ApoA-I levels for most individuals and measured directly in blood for a few others.(10)

Severe infections

We defined severe infections as a hospitalization for infectious diseases or a diagnosis of sepsis through the Swedish Patient Register. As milder infections will generally not lead to hospitalization and may only be recorded as secondary diagnoses in inpatient care, we identified hospitalizations for infectious diseases using the primary diagnosis of an inpatient care episode only. In contrast, sepsis was identified using both primary and secondary diagnoses from both inpatient and outpatient care. Table S1 shows the Swedish versions of the ICD codes used to ascertain these outcomes.

Covariates

We obtained information on sex and birth year from the AMORIS cohort laboratory data, as well as data on country of birth, education, income, and employment status from the Swedish Population and Housing Census (FOB) in 1985 and the Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA) with annually updated information from 1990 onward. As education, income, and employment status were considered as potential confounders for the associations between biomarker trajectories within 10 years prior to cancer diagnosis and risk of severe infections after cancer diagnosis, we defined these covariates using available data closest in time to the first blood sampling during this time period. Individuals with missing values in these covariates were classified into an unknown category. We considered severe infections (both hospitalization for infectious diseases and a

diagnosis of sepsis) during the 10 years before cancer diagnosis as well as history of diabetes and psychiatric disorders any time before cancer diagnosis as additional covariates.

Statistical analysis

We first used latent class growth modeling (LCGM) to identify latent classes of trajectories of the 18 selected biomarkers during the 10 years before cancer diagnosis. We conducted three crude models with two polynomial functions of time (linear and quadratic) for biomarker trajectories: fixed effect only, fixed effect with random intercept, and fixed effect with both random intercept and slope. We analyzed one to five classes in each polynomial model. A log-transformation was used for all biomarkers in the LCGM analysis. The best-fit model was determined if the model had the lowest BIC with $P<0.05$ for all polynomial terms and a group membership probability of ≥5%. At the end, quadratic models were selected for ApoA1, triglycerides, HDL, hemoglobin, albumin, haptoglobin, and CRP, while linear models were selected for the other biomarkers (Table S3).

We then employed flexible parametric models to visualize hazards and hazard ratios (HRs) of severe infections in relation to pre-diagnostic biomarker trajectories by time since cancer diagnosis. Flexible parametric models allow for evaluating time-varying effect of exposure. As HRs were largely constant during the follow-up for most biomarker trajectories (Figure S1a for hospitalization for infectious diseases and Figure S1b for sepsis), we reported average HRs and 95% confidence intervals (CIs) for the sake of simplicity. The classes with the largest number of cancer patients were defined as reference, whereas time since cancer diagnosis was used as the underlying time scale in the analyses. We conducted a multivariable model with the adjustment for sex, age and calendar year at cancer diagnosis, and country of birth, education, income, and employment status at the time of first blood sampling. To minimize potential confounding by comorbidities, we performed a sensitivity analysis by additionally adjusting for severe infections within the 10 years before cancer diagnosis, as well as any history of diabetes or psychiatric disorders before cancer diagnosis. To assess the robustness of the results for the ascertainment of hospitalization for infectious diseases via primary diagnosis only, we conducted a sensitivity analysis to consider both primary and secondary diagnoses when defining hospitalization for infectious diseases.

To evaluate if the associations between biomarker trajectories and severe infections differed by sex, age at cancer diagnosis, and history of severe infections during the 10 years before cancer diagnosis, we performed stratified analyses by these factors. Finally, to examine whether the results were specific to cancer types, we investigated the associations among patients with the three most common types of cancer in this cohort, namely cancer in breast or reproductive system, cancer in the digestive system, and hematological malignancies, separately.

The study was approved by the Swedish Ethical Review Authority (2020-01545). Analyses were performed in SAS 9.4 and R 4.3.1.

Results

Among the 10,837 cancer patients included in the study [mean age at diagnosis (standard deviation): 65.9 (11.7) years], 5476 (50.5%) were men, 4185 (38.6%) were diagnosed during 1985-1995, and 9385 (86.6%) were born in Sweden (Table 1). During the follow-up, 3752 (34.6%) of these patients had at least one hospitalization for infectious diseases whereas 1709 (15.8%) had a diagnosis of sepsis. Compared to patients without any hospitalization for infectious diseases by the end of follow-up, those with such experience were more likely to be employed, have higher income, and have had a severe infection during the 10 years before cancer diagnosis.

Biomarker trajectories during the 10 years before cancer diagnosis

We identified two latent classes for most metabolic biomarkers, except for LDL, which exhibited four parallel trajectories (Figure 2). The trajectories of glucose, fructosamine, TC, triglycerides, and HDL showed consistently high or low levels during the 10 years before cancer diagnosis. The trajectories of LDL/HDL ratio, ApoB, and ApoB/ApoA1 ratio showed different patterns, with one trajectory showing stable levels whereas the other showing initially high levels followed by a constant decline over time. The two trajectories of ApoA1 were close to each other throughout the 10-year period.

Two distinct trajectories were identified for globulin, CRP, and IgG, whereas three trajectories were identified for the other inflammatory biomarkers. Globulin exhibited two trajectories with consistently high or low levels over time, whereas CRP and IgG showed one trajectory with stable levels and another with increasing levels over time. Hemoglobin, haptoglobin, and uric acid displayed in general three parallel trajectories. Leukocytes showed one trajectory of increasing levels and two trajectories of stable levels, whereas albumin showed two trajectories with relatively high and stable levels but one trajectory that started at low levels with further decline over time.

Associations between biomarker trajectories and severe infections after cancer diagnosis

The hazard of severe infections defined as either hospitalization for infectious diseases or a diagnosis of sepsis was highest shortly after cancer diagnosis, followed by a marked decrease during the first five years and a continuous increase during the 5-35 years after cancer diagnosis (Figure 3a for hospitalization for infectious diseases and Figure 3b for sepsis). Similar trends were observed in the sensitivity analysis where hospitalization for infectious diseases was defined by both primary and secondary diagnoses, although the further increase more than five years after cancer diagnosis was not as evident (Figure S2).

We observed that cancer patients with persistently high levels of glucose and fructosamine during the 10 years before diagnosis had a 54% to 83% higher risk of severe infections after diagnosis, compared to those with persistently low levels during the 10 years before cancer diagnosis (Figure 4). Similar but weaker associations were found for triglycerides. In contrast, cancer patients with persistently low levels of TC and HDL had a slightly higher (5% to 22%) risk of severe infections. Further, patients with initially high but continuously declining ApoB levels during the 10 years before cancer diagnosis had a 31% to 53% higher risk of severe

infections compared to patients with persistently low levels. No association was found for the trajectories of LDL, LDL/HDL ratio, ApoA1, or ApoB/ApoA1 ratio.

Cancer patients with persistently high levels of globulin during the 10 years before cancer diagnosis had about 20% higher risk of severe infections than those with persistently low levels. Patients whose CRP and IgG levels were initially low but rapidly increased during the five or 10 years prior to cancer diagnosis had an elevated risk of severe infections, compared to those with persistently low levels of CRP or IgG. In contrast, patients with consistently low levels in leukocyte count before cancer diagnosis had a 69% lower risk of hospitalization for infectious diseases, compared with those with persistently intermediate levels. We did not find any association for other inflammatory biomarkers.

We found similar results after additionally adjusting for history of severe infections during the 10 years before cancer diagnosis and psychiatric disorders and diabetes any time before cancer diagnosis (Table S4), or when considering both primary and secondary diagnoses for the ascertainment of hospitalization for infectious diseases (Table S5).

Compared to men, women had a greater risk increase in hospitalization for infectious diseases in relation to persistently high trajectories of glucose, fructosamine, and triglycerides as well as the persistently low trajectory of HDL, but a lower risk increase in relation to the persistently high trajectory of globulin (Table S6). The elevated risk of hospitalization for infectious diseases in relation to specific trajectories of glucose, fructosamine, ApoB, ApoB/ApoA1 ratio, and CRP was greater among patients diagnosed with cancer at age 60 or younger, compared to patients diagnosed later in life (Table S7). We observed stronger associations for trajectories of glucose and fructosamine among patients without a history of severe infections during the 10 years before cancer diagnosis, compared with those with such history; however, the pattern was opposite for the trajectories of HDL and globulin (Table S8). The elevated risk of hospitalization for infectious diseases in relation to trajectories of fructosamine and ApoB was greatest among patients with hematological malignancies, compared to patients with other two cancer types; however, the association for trajectories of IgG was most pronounced among patients with cancer in breast and reproductive system (Table S9).

Discussion

In this large Swedish cohort study, we identified several distinct trajectories for 18 metabolic and inflammatory blood biomarkers during the 10 years before a cancer diagnosis. Patients with consistently high levels of glucose, fructosamine, triglycerides, or globulin during the 10 years prior to cancer diagnosis had a higher risk of severe infections, compared to those with persistently low levels. Conversely, patients with persistently low levels of TC or HDL exhibited a slightly higher risk of severe infections than those with persistently high levels. An increasing level of inflammatory biomarkers, e.g., CRP and IgG, particularly during the five years before diagnosis, was associated with a higher risk of severe infections, while

patients with consistently low leukocyte counts had a lower risk of severe infections, compared to others.

Our finding on the risk of severe infections align with previous research, which also reported that the risk of sepsis peaked shortly after cancer diagnosis and decreased over time.(6) The observed decreased levels of TC and LDL and increased levels of glucose before cancer diagnosis are also consistent with findings from existing studies.(7, 8) Similarly, increased CRP and IgG levels have also been reported in previous studies.(11) The present study extends therefore the existing knowledgebase by characterizing trajectories of 18 metabolic and inflammatory biomarkers over a time period of 10 years before cancer diagnosis as well as by assessing the associations of such trajectories with risk of severe infections post-cancer diagnosis.

Inflammation is a recognized hallmark of cancer development and progression.(11) Elevated circulating levels of inflammatory biomarkers, such as CRP, have been associated with an increased risk of cancer development in various populations, including the AMORIS cohort,(12-15) whereas higher pre-diagnostic levels of haptoglobin and CRP have been linked to an increased risk of premature death among patients with breast cancer.(16) The present study corroborates this hypothesis by showing that increasing levels of CRP and IgG during the five years before cancer diagnosis are associated with a heightened risk of severe infections, whereas consistently low leukocyte counts during the 10 years before cancer diagnosis were linked to a reduced risk of severe infections after cancer diagnosis. Taken together, these results highlight the important role of inflammation and immune dysregulation in cancer development, as well as patient survival and adverse health outcomes (e.g., infections) following diagnosis.(17)

Hyperglycemia prior to cancer diagnosis may contribute to infection risk by impairing immune function, such as neutrophil activity, and disrupting gastrointestinal and urinary systems.(18) Our study found that patients with persistently high glucose (8.0~11.5 mmol/L) and fructosamine (2.6~3.0 mmol/L) levels before cancer diagnosis had a higher risk of severe infections compared to those with persistently low levels. These results align with existing evidence showing that cancer patients with diabetes are at higher risk of infections, particularly within 90 days after initiating chemotherapy.(19, 20) Moreover, diabetes and hyperglycemia have been associated with increased mortality among cancer patients.(21-23) Nevertheless, prior research has reported that glucose levels within this range were linked to the lowest sepsis risk among individuals with type 2 diabetes,(24) suggesting that a less stringent glucose control strategy may be appropriate for that population.(25) In contrast, our findings imply that stricter glucose control may be warranted among cancer patients to reduce the risk of sepsis.

Lipids play a crucial role in modulating infection risk in both cancer patients and the general population. Our study showed that persistently high triglyceride levels or low HDL levels were associated with an increased risk of severe infections, consistent with findings in non-cancer populations.(26-28) Cholesterol, particularly LDL and HDL, binds and neutralizes lipopolysaccharides (LPS), protecting against LPS-induced toxicity.(28, 29) Furthermore,

lipids facilitate viral replication by regulating membrane trafficking, providing structural components for cellular membranes, and supplying energy for viral replication.(30-32) Dyslipidemia has also been linked to an increased risk of COVID-19 infection among patients with breast cancer.(33)

The strengths of our study include the use of large-scale cohort data with repeated biomarker measurements and high-quality follow-up data from nationwide Swedish health registers. Importantly, information on severe infections was collected independently of biomarker measurements. Repeated measurements provide a more comprehensive assessment of a biomarker over time compared to a single snap-shot measurement. Specifically, our results demonstrated that the trajectories of ApoB, CRP, and IgG intersected over the 10-year period and were associated with an increased risk of severe infections after cancer diagnosis. These findings suggest that relying on a single measurement of these biomarkers prior to cancer diagnosis may result in substantial misclassification of patients at elevated risk for severe infections. Furthermore, all blood samples in the AMORIS cohort were analyzed in the same clinical laboratory following well documented and consistently applied standard procedures, ensuring comparability of biomarker measurements between individuals and across different time points. Nevertheless, some limitations should be acknowledged. First, requiring at least three blood samplings before cancer diagnosis may have introduced selection bias. However, no substantial differences were observed in the characteristics of the included and excluded cancer patients. Second, due to limited statistical power, we were unable to analyze the associations between biomarker trajectories and severe infections for all cancer types, although subgroup analyses were performed for the three most common cancer types categorized by organ system. Third, despite adjusting for multiple covariates, residual confounding from unknown or unmeasured confounders such as genetic factors, smoking, body mass index, or alcohol consumption remains possible. Fourth, in the Swedish Cause of Death Register, the underlying cause of death for cancer patients who died with severe infection is largely recorded as cancer, since the register defines the underlying cause as the disease or injury that initiates the chain of morbid events leading directly to death.

Conclusion

We identified distinct trajectories of metabolic and inflammatory biomarkers during the ten years preceding cancer diagnosis. Specific trajectories, such as persistently high levels of glucose, fructosamine, triglycerides, and globulin, or increasing levels of CRP and IgG, were associated with an elevated risk of severe infections after cancer diagnosis. These findings suggest that longitudinal surveillance of metabolic and inflammatory blood biomarkers before cancer diagnosis could help guide infection prevention and management strategies in cancer patients.

Funding

The study was supported by the ìShizu Matsumuraîs Donation (grant no. FS-2023:0003) and the Swedish Cancer Society (grant no. 23 2741Pj). This study was also partially supported by the Initial Founding for High Level Talented Scholars in Nanfang Hospital, Southern Medical University (No. 2023G001) and the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University (Grant No. 2023J009) to QL. DW was supported by the International Postdoc Grant from the Swedish Research Council (grant no. 2023-00206).

Disclosure of interest

The authors have no potential conflicts of interest to disclose.

Reference

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.
2. Zembower TR. Epidemiology of Infections in Cancer Patients. In: Stosor V, Zembower TR, editors. Infectious Complications in Cancer Patients. Cham: Springer International Publishing; 2014. p. 43-89.
3. Rolston KVI. Infections in Cancer Patients with Solid Tumors: A Review. Infectious Diseases and Therapy. 2017;6(1):69-83.
4. Elhadi M, Khaled A, Msherghi A. Infectious diseases as a cause of death among cancer patients: a trend analysis and population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results database. Infect Agent Cancer. 2021;16(1):72.
5. Homsi J, Walsh D, Panta R, Lagman R, Nelson KA, Longworth DL. Infectious complications of advanced cancer. Support Care Cancer. 2000;8(6):487-92.
6. Liu Q, Song H, Andersson TM, Magnusson PKE, Zhu J, Smedby KE, et al. Psychiatric Disorders Are Associated with Increased Risk of Sepsis Following a Cancer Diagnosis. Cancer Res. 2020;80(16):3436-42.
7. Sah RP, Sharma A, Nagpal S, Patlolla SH, Sharma A, Kandlakunta H, et al. Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2019;156(6):1742-52.
8. Klatte DCF, Weston A, Ma Y, Sledge H, Bali A, Bolan C, et al. Temporal Trends in Body Composition and Metabolic Markers Prior to Diagnosis of Pancreatic Ductal Adenocarcinoma. Clin Gastroenterol Hepatol. 2024;22(9):1830-8.e9.
9. Walldius G, Malmström H, Jungner I, de Faire U, Lambe M, Van Hemelrijck M, et al. Cohort Profile: The AMORIS cohort. Int J Epidemiol. 2017;46(4):1103-i.
10. Chourpiliadis C, Zeng Y, Lovik A, Wei D, Valdimarsdóttir U, Song H, et al. Metabolic Profile and Long-Term Risk of Depression, Anxiety, and Stress-Related Disorders. JAMA Netw Open. 2024;7(4):e244525.
11. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27-41.
12. Sollie S, Michaud DS, Sarker D, Karagiannis SN, Josephs DH, Hammar N, et al. Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study. BMC Cancer. 2019;19(1):858.
13. Zhou B, Shu B, Yang J, Liu J, Xi T, Xing Y. C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis. Cancer Causes Control. 2014;25(10):1397-405.
14. Allin KH, Bojesen SE, Nordestgaard BG. Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population. Int J Cancer. 2016;139(7):1493-500.
15. Zeng F, Wei H, Yeoh E, Zhang Z, Ren ZF, Colditz GA, et al. Inflammatory Markers of CRP, IL6, TNFα, and Soluble TNFR2 and the Risk of Ovarian Cancer: A Meta-analysis of Prospective Studies. Cancer Epidemiol Biomarkers Prev. 2016;25(8):1231-9.
16. Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, et al. Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients. Carcinogenesis. 2015;36(10):1121-8.
17. Rossi JF, Lu ZY, Massart C, Levon K. Dynamic Immune/Inflammation Precision Medicine: The Good and the Bad Inflammation in Infection and Cancer. Front Immunol. 2021;12:595722.
18. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab. 2012;16 Suppl 1(Suppl1):S27-36.

19. Srokowski TP, Fang S, Hortobagyi GN, Giordano SH. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol. 2009;27(13):2170-6.
20. Mailliez A, Ternynck C, Duhamel A, Mailliez A, Ploquin A, Desauw C, et al. Diabetes is associated with high risk of severe adverse events during chemotherapy for cancer patients: A single-center study. Int J Cancer. 2023;152(3):408-16.
21. Ali NA, O'Brien JM, Jr., Blum W, Byrd JC, Klisovic RB, Marcucci G, et al. Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer. 2007;110(1):96-102.
22. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. Jama. 2008;300(23):2754-64.
23. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care. 2010;33(4):931-9.
24. Balintescu A, Lind M, Franko MA, Oldner A, Cronhjort M, Svensson AM, et al. Glycemic Control and Risk of Sepsis and Subsequent Mortality in Type 2 Diabetes. Diabetes Care. 2022;45(1):127-33.
25. Hirasawa H, Oda S, Nakamura M. Blood glucose control in patients with severe sepsis and septic shock. World J Gastroenterol. 2009;15(33):4132-6.
26. Guirgis FW, Donnelly JP, Dodani S, Howard G, Safford MM, Levitan EB, et al. Cholesterol levels and long-term rates of community-acquired sepsis. Crit Care. 2016;20(1):408.
27. Hamilton F, Pedersen KM, Ghazal P, Nordestgaard BG, Smith GD. Low levels of small HDL particles predict but do not influence risk of sepsis. Crit Care. 2023;27(1):389.
28. Wendel M, Paul R, Heller AR. Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med. 2007;33(1):25-35.
29. Catapano AL, Pirillo A, Bonacina F, Norata GD. HDL in innate and adaptive immunity. Cardiovasc Res. 2014;103(3):372-83.
30. Masana L, Correig E, Ibarretxe D, Anoro E, Arroyo JA, Jericó C, et al. Low HDL and high triglycerides predict COVID-19 severity. Sci Rep. 2021;11(1):7217.
31. Nagy PD, Strating JR, van Kuppeveld FJ. Building Viral Replication Organelles: Close Encounters of the Membrane Types. PLoS Pathog. 2016;12(10):e1005912.
32. Diamond DL, Syder AJ, Jacobs JM, Sorensen CM, Walters KA, Proll SC, et al. Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog. 2010;6(1):e1000719.
33. Shakartalla SB, Alhumaidi RB, Shammout ODA, Al Shareef ZM, Ashmawy NS, Soliman SSM. Dyslipidemia in breast cancer patients increases the risk of SAR-CoV-2 infection. Infect Genet Evol. 2021;92:104883.

Figure legends

Figure 1. Flowchart of study design based on the Swedish AMORIS cohort

Figure 2. Latent classes of metabolic and inflammatory biomarker trajectories within 10 years before cancer diagnosis

TC=total cholesterol; HDL=high-density lipoprotein; LDL=low-density lipoprotein; ApoA1=apolipoprotein A1; ApoB=apolipoprotein B; CRP=C-reactive protein; IgG=immunoglobulin G

Glucose (Class 1: stable at low levels; Class 2: started at high levels and increased); Fructosamine (Class 1: stable at low levels; Class 2: started at high levels and slightly increased); TC (Class 1: stable at low levels; Class 2: stable at high levels); Triglycerides (Class 1: started at high levels, remained stable, then decreased; Class 2: stable at low levels); HDL (Class 1: started at high levels, remained stable, then slightly decreased; Class 2: stable at low levels); LDL (Class 1: stable at low levels; Class 2: stable at middle levels; Class 3: stable at high-middle levels; Class 4: stable at high levels); LDL/HDL ratio (Class 1: started at high levels and decreased; Class 2: stable at low levels); ApoA1 (Class 1: slight increase followed by a decrease; Class 2: slight decrease followed by an increase); ApoB (Class 1: started at high levels and decreased; Class 2: stable at low levels); ApoB/ApoA1 ratio (Class 1: started at high levels and decreased; Class 2: stable at low levels); Hemoglobin (Class 1: started at low levels, remained stable, then decreased; Class 2: stable at intermediate levels; Class 3: stable at high levels); Globulin (Class 1: stable at low levels; Class 2: started at high levels and slightly increased); Haptoglobin (Class 1: stable at low levels; Class 2: stable at intermediate levels; Class 3: stable at high levels); CRP (Class 1: started low levels, remained stable, then increased rapidly; Class 2: started at relatively higher levels but remained stable); IgG (Class 1: stable at low levels; Class 2: started at low levels and increased rapidly); Leukocyte (Class 1: stable at intermediate levels; Class 2: stable at low levels; Class 3: started at high levels and increased); Uric acid (Class 1: stable at low levels; Class 2: stable at intermediate levels; Class 3: stable at high levels); Albumin (Class 1: started at low levels, remained stable, then decreased; Class 2: stable at intermediate levels; Class 3: stable at high levels).

Figure 3. Hazards of severe infections (a. hospitalization for infectious diseases and b. diagnosis of sepsis) after a cancer diagnosis in relation to biomarker trajectories

TC=total cholesterol; HDL=high-density lipoprotein; LDL=low-density lipoprotein; ApoA1=apolipoprotein A1; ApoB=apolipoprotein B; CRP=C-reactive protein; IgG=immunoglobulin G

Figure 4. Associations of biomarker trajectories with hospitalization for infectious disease and sepsis

TC=total cholesterol; HDL=high-density lipoprotein; LDL=low-density lipoprotein; ApoA1=apolipoprotein A1; ApoB=apolipoprotein B; CRP=C-reactive protein; IgG=immunoglobulin G

Adjusted for sex, calendar year of cancer diagnosis, age at cancer diagnosis, country of birth, education, income, and employment status at the first blood sampling.
*rate: per 1000 person-years.

Table 1. Characteristics of the cancer patients included in the present study according to hospitalization for infectious disease during follow-up

Characteristics	Hospitalization for infectious disease	No hospitalization for infectious disease	Overall
	(N=3752)	(N=7085)	(N=10,837)
Sex: male, N (%)	1920 (51.2)	3556 (50.2)	5476 (50.5)
Age at diagnosis, mean (SD)	65.7 (11.3)	66.0 (11.9)	65.9 (11.7)
Calendar year at diagnosis, N (%)			
1985-1995	1347 (35.9)	2838 (40.1)	4185 (38.6)
1996-2005	2405 (64.1)	4247 (59.9)	6652 (61.4)
Country of birth, N (%)			
Sweden	3256 (86.8)	6129 (86.5)	9385 (86.6)
Elsewhere	496 (13.2)	956 (13.5)	1452 (13.4)
Education at the first blood sampling, N (%)			
Primary	859 (22.9)	1664 (23.5)	2523 (23.3)
Secondary	1819 (48.5)	3241 (45.7)	5060 (46.7)
Tertiary	919 (24.5)	1537 (21.7)	2456 (22.7)
Unknown	155 (4.1)	643 (9.1)	798 (7.4)
Employment status at the first blood sampling, N (%)			
Non-gainfully employed or unemployed	926 (24.7)	1987 (28.0)	2913 (26.9)
Gainfully employed	2811 (74.9)	5056 (71.4)	7867 (72.6)
Unknown	15 (0.4)	42 (0.6)	57 (0.5)
Income at the first blood sampling, N (%)			
Below 1st tertile	1235 (32.9)	2533 (35.8)	3768 (34.8)
1st-2nd tertile	1093 (29.1)	2103 (29.7)	3196 (29.5)
Above 2nd tertile	1417 (37.8)	2432 (34.3)	3849 (35.5)
Unknown	7 (0.2)	17 (0.2)	24 (0.2)
Severe infections during the 10 years before cancer diagnosis: yes, N (%)∗	540 (14.4)	840 (11.9)	1380 (12.7)
Psychiatric disorders before cancer diagnosis: yes, N (%)	304 (8.1)	603 (8.5)	907 (8.4)
Diabetes before cancer diagnosis: yes, N (%)	248 (6.6)	476 (6.7)	724 (6.7)

SD = standard deviation

∗Severe infections included hospitalization for infectious diseases and any diagnosis of sepsis at a hospital visit.


812,073 individuals enrolled in the Swedish AMORIS cohort during 1985-1996
634,981 individuals with at least one blood test
73,739 individuals diagnosed with cancer during 1985-2005
40,483 cancer patients with at least one blood test within 10 years before the diagnosis
10,837 cancer patients with at least three blood tests within 10 years before the diagnosis who were included in the analysis


Glucose (n=9890)
Glucose (mmol/L)
Fructosamine (n=9353)
Fructosamine (mmol/L)
TC (n=10,370)
TC (mmol/L)
Triglycerides (n=10,329)
Triglycerides (mmol/L)
HDL (n=5555)
HDL (mmol/L)
LDL (n=5750)
LDL (mmol/L)
LDL/HDL ratio (n=5555)
LDL/HDL ratio
ApoA1 (n=5812)
ApoA1 (g/L)
ApoB (n=5623)
ApoB (g/L)
ApoB/ApoA1 ratio (n=5419)
ApoB/ApoA1 ratio
Hemoglobin (n=6600)
Hemoglobin (g/L)
Globulin (n=5688)
Globulin (g/L)
Haptoglobin (n=8506)
Haptoglobin (g/L)
CRP (n=8586)
CRP (g/L)
IgG (n=3482)
IgG (g/L)
Leukocyte (n=6447)
Leukocyte (10^9/L)
Uric acid (n=10,109)
Uric acid (µmol/L)
Albumin (n=10,403)
Albumin (g/L)
Time To Cancer Diagnosis (Years)
Class 1
Class 2
Class 3
Class 4


Glucose
Fructosamine
TC
Triglycerides
HDL
LDL
LDL/HDL ratio
ApoA1
ApoB
ApoB/ApoA1 ratio
Hemoglobin
Globulin
Haptoglobin
CRP
IgG
Leukocyte
Uric acid
Albumin
Hazard (per person−year)
Time Since Cancer diagnosis (years)
Class 1
Class 2
Class 3
Class 4


Glucose
Fructosamine
TC
Triglycerides
HDL
LDL
LDL/HDL ratio
ApoA1
ApoB
ApoB/ApoA1 ratio
Hemoglobin
Globulin
Haptoglobin
CRP
IgG
Leukocyte
Uric acid
Albumin
Hazard (per person−year)
Time Since Cancer diagnosis (years)
Class 1
Class 2
Class 3
Class 4

Groups	N	Hospitalization for infection Events/rate*	HR (95%CI)	Sepsis Events/rate*	HR (95%CI)
Glucose					
Class 1: Stable at low levels	9268	3228/39.5	Ref.	1450/15.1	Ref.
Class 2: Started at high levels and increased	622	215/77.5	1.54 (1.34−1.78)	108/31	1.63 (1.33−1.99)
Fractosamine					
Class 1: Stable at low levels	8962	3104/39.6	Ref.	1406/15.3	Ref.
Class 2: Started at high levels and slightly increased	391	138/78.9	1.65 (1.38−1.97)	72/33.6	1.83 (1.44−2.33)
TC					
Class 1: Stable at low levels	4417	1506/39.3	1.05 (0.98−1.13)	719/16	1.13 (1.02−1.25)
Class 2: Stable at high levels	5953	2108/42.9	Ref.	927/16	Ref.
Triglycerides					
Class 1: Started at high levels, remained stable, then decreased	1362	492/53.2	1.25 (1.13−1.37)	236/21.1	1.21 (1.05−1.39)
Class 2: Stable at low levels	8967	3108/39.9	Ref.	1397/15.3	Ref.
HDL					
Class 1: Started at high levels, remained stable, then slightly decreased	3244	1155/38.7	Ref.	509/14.6	Ref.
Class 2: Stable at low levels	2311	853/49.7	1.22 (1.11−1.34)	406/19.9	1.15 (1.00−1.33)
LDL					
Class 1: Stable at low levels	354	116/38.3	0.81 (0.09−7.58)	61/17	0.30 (0.02−5.14)
Class 2: Stable at middle levels	1377	492/44.2	0.78 (0.21−2.94)	220/16.8	0.41 (0.07−2.51)
Class 3: Stable at high−middle levels	2937	1061/42.8	Ref.	499/17.1	Ref.
Class 4: Stable at high levels	1082	399/43.4	2.27 (0.68−7.57)	168/15.5	0.77 (0.13−4.42)
LDL/HDL ratio					
Class 1: Started at high levels and decreased	121	54/54.9	1.16 (0.88−1.53)	21/17.5	1.00 (0.64−1.56)
Class 2: Stable at low levels	5434	1954/42.5	Ref.	894/16.5	Ref.
ApoA1					
Class 1: Slight increase followed by a decrease	2957	1038/41.7	Ref.	475/16.2	Ref.
Class 2: Slight decrease followed by an increase	2855	1055/44.3	1.05 (0.96−1.15)	486/17.2	1.02 (0.89−1.16)
ApoB					
Class 1: Started at high levels and decreased	148	65/55.4	1.31 (1.01−1.68)	34/24.7	1.53 (1.08−2.18)
Class 2: Stable at low levels	5475	1962/42.4	Ref.	885/16.2	Ref.
ApoB/ApoA1 ratio					
Class 1: Started at high levels and decreased	230	96/50.9	1.14 (0.93−1.40)	37/15.6	0.84 (0.60−1.18)
Class 2: Stable at low levels	5189	1877/43.4	Ref.	859/16.9	Ref.
Hemoglobin					
Class 1: Started at low levels, remained stable, then derecreased	622	206/44.9	0.86 (0.14−5.47)	95/17.3	0.41 (0.03−5.82)
Class 2: Stable at intermediate levels	3499	1266/43.4	Ref.	528/15.2	Ref.
Class 3: Stable at high levels	2479	898/50	2.37 (0.90−6.23)	411/19.1	1.66 (0.48−5.79)
Globulin					
Class 1: Stable at low levels	4184	1517/39.3	Ref.	666/14.7	Ref.
Class 2: Started at high levels and slightly increased	1504	502/50.8	1.21 (1.09−1.34)	233/19.4	1.25 (1.07−1.46)
Haptoglobin					
Class 1: Stable at low levels	1220	435/34.4	0.69 (0.14−3.29)	203/13.8	0.91 (0.16−5.14)
Class 2: Stable at intermediate levels	2088	662/52.4	0.50 (0.16−1.54)	307/20.2	2.27 (0.67−7.64)
Class 3: Stable at high levels	5198	1808/37.5	Ref.	804/14.2	Ref.
CRP					
Class 1: Started at low levels, remained stable, then increased rapidly	776	264/53.6	1.25 (1.10−1.43)	137/23.8	1.41 (1.18−1.69)
Class 2: Started at relatively higher levels but remained stable	7810	2773/40.5	Ref.	1251/15.5	Ref.
IgG					
Class 1: Stable at low levels	3398	1146/41.7	Ref.	491/15.1	Ref.
Class 2: Started at low levels and increased rapidly	84	29/79.4	1.85 (1.24−2.76)	19/40.7	2.13 (1.27−3.58)
Leukocyte					
Class 1: Stable at intermediate levels	3131	1110/52	Ref.	464/18	Ref.
Class 2: Stable at low levels	2973	1091/41	0.31 (0.11−0.86)	481/15.3	0.42 (0.12−1.51)
Class 3: Started at high levels and increased	343	117/61.1	0.11 (0.01−1.34)	54/23.3	0.04 (0.00−1.83)
Uric acid					
Class 1: Stable at low levels	1968	667/31.5	0.53 (0.16−1.76)	261/10.5	0.88 (0.17−4.51)
Class 2: Stable at intermediate levels	5082	1722/39.5	Ref.	758/14.8	Ref.
Class 3: Stable at high levels	3059	1122/55.6	0.75 (0.31−1.80)	579/24.2	1.60 (0.56−4.57)
Albumin					
Class 1: Started at low levels, remained stable, then derecreased	483	128/56.1	0.48 (0.07−3.53)	72/27.3	0.60 (0.04−9.74)
Class 2: Stable at intermediate levels	4818	1623/43.9	0.73 (0.33−1.63)	716/16.4	1.70 (0.64−4.56)
Class 3: Stable at high levels	5102	1846/39.2	Ref.	847/15.3	Ref.